LataMed AI Corp. (OTC: LMED), a development-stage digital health and AI technology company, announced today that it has begun a strategic evaluation with Vertice Seguros, a Venezuelan insurance provider, to explore combining insurance products with its expanding digital healthcare ecosystem. The initiative aims to make life and health insurance accessible through LataMed AI's platforms while granting Vertice Seguros clients access to telehealth, care coordination, healthcare analytics, and AI-enabled solutions.
Management believes the proposed collaboration could create complementary commercial opportunities by expanding customer reach, increasing healthcare accessibility, enhancing patient engagement, and promoting technology-enabled healthcare and financial protection solutions across Latin America. Preliminary evaluations are underway, focusing on user onboarding, platform integration, operational workflows, regulatory considerations, and commercialization potential.
Dr. Kevin Rodan Levy, CEO of LataMed AI Corp., stated: "Our vision is to create a more connected healthcare ecosystem where technology, care delivery, and financial protection solutions work together to improve accessibility and outcomes. We believe this evaluation process with Vertice Seguros represents an opportunity to explore how healthcare technology services and insurance solutions can be combined within a unified digital platform."
The evaluation aligns with LataMed AI's broader strategy of building an integrated healthcare ecosystem combining AI, telehealth, analytics, care coordination, pharmacy connectivity, and emergency response. The company focuses on emerging markets where healthcare access is limited. The initiative underscores the growing trend of integrating insurance with digital health to improve patient engagement and outcomes.
Any definitive arrangement would be subject to successful completion of evaluations, negotiation of final terms, regulatory approvals, and execution of definitive agreements. LataMed AI intends to provide updates as material developments occur.
For more information, visit https://latamed.ai or review SEC filings at https://www.sec.gov.
